Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc., a company specializing in regenerative medicine, is well-positioned for growth due to an anticipated improvement in valuation as solid financial results are expected amidst current market dynamics. The final reimbursement rate for the company’s products has increased slightly to $127.28/cm² for CY2026, which suggests an upward trend in operational profitability over time. Additionally, the company is expected to capture a greater market share in a consolidating industry, with shares trading significantly below its peer set, indicating substantial potential for future gains.

Bears say

Organogenesis Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock. Key concerns include the potential for lower-than-expected growth in the PuraPly product line, pricing pressures from Medicare Part B on amniotic products, and the increased efficiency of competitors that could hinder market share gains. Additionally, uncertainties surrounding clinical outcomes, lower uptake of new products, and a possible reduction in sales force efficiencies could further undermine the company's financial performance moving forward.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.